Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis

Florian Anzengruber,1,2 Adhideb Ghosh,1–3 Julia-Tatjana Maul,1,2 Mathias Drach,1,2 Alexander A Navarini1–3 1Department of Dermatology, University Hospital Zurich, Zurich, Switzerland; 2Faculty of Medicine, University of Zurich, Zurich, Switzerland; 3Competence Center Personalized...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anzengruber F, Ghosh A, Maul JT, Drach M, Navarini AA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	human leucocyte antigen Cw6 genetic variations HLA - Cw6 ustekinumab. Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/b23c615b37b24ed0ba058906bc897a55
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b23c615b37b24ed0ba058906bc897a55
record_format	dspace
spelling	oai:doaj.org-article:b23c615b37b24ed0ba058906bc897a552021-12-02T01:46:52ZLimited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis2230-326Xhttps://doaj.org/article/b23c615b37b24ed0ba058906bc897a552018-03-01T00:00:00Zhttps://www.dovepress.com/limited-clinical-utility-of-hla-cw6-genotyping-for-outcome-prediction--peer-reviewed-article-PTThttps://doaj.org/toc/2230-326XFlorian Anzengruber,1,2 Adhideb Ghosh,1–3 Julia-Tatjana Maul,1,2 Mathias Drach,1,2 Alexander A Navarini1–3 1Department of Dermatology, University Hospital Zurich, Zurich, Switzerland; 2Faculty of Medicine, University of Zurich, Zurich, Switzerland; 3Competence Center Personalized Medicine University of Zurich/Swiss Federal Institute of Technology (ETH) Zurich, Switzerland Purpose: Several studies have suggested that an HLA-Cw6+ allele can predict an improved outcome of treatment in psoriasis patients. The aim of the study was to assess whether the published association between HLA-Cw6 allele carriers and response to ustekinumab has the potential to impact treatment decisions. Patients and methods: Differences in Psoriasis Activity and Severity Index 50, 75, and 90; Nail Psoriasis Severity Index; and Dermatology Life Quality Index at 16 weeks were evaluated between HLA-Cw6 allele carriers vs. non-carriers. Thirty patients with moderate-to-severe psoriasis under treatment with ustekinumab were included in our study. Results: There was no difference between the two groups with respect to Psoriasis Activity and Severity Index 50, 75, and 90 or in terms of change in Nail Psoriasis Severity Index or Dermatology Life Quality Index. Conclusion: In our retrospectively analyzed cohort, we could not detect the previously reported better response in HLA-Cw6+ vs. HLA-Cw6− patients. Keywords: human leukocyte antigen, Cw6, genetic variations, HLA-Cw6, ustekinumabAnzengruber FGhosh AMaul JTDrach MNavarini AADove Medical Pressarticlehuman leucocyte antigenCw6genetic variationsHLA - Cw6ustekinumab. DermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol Volume 8, Pp 7-11 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	human leucocyte antigen Cw6 genetic variations HLA - Cw6 ustekinumab. Dermatology RL1-803
spellingShingle	human leucocyte antigen Cw6 genetic variations HLA - Cw6 ustekinumab. Dermatology RL1-803 Anzengruber F Ghosh A Maul JT Drach M Navarini AA Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis
description	Florian Anzengruber,1,2 Adhideb Ghosh,1–3 Julia-Tatjana Maul,1,2 Mathias Drach,1,2 Alexander A Navarini1–3 1Department of Dermatology, University Hospital Zurich, Zurich, Switzerland; 2Faculty of Medicine, University of Zurich, Zurich, Switzerland; 3Competence Center Personalized Medicine University of Zurich/Swiss Federal Institute of Technology (ETH) Zurich, Switzerland Purpose: Several studies have suggested that an HLA-Cw6+ allele can predict an improved outcome of treatment in psoriasis patients. The aim of the study was to assess whether the published association between HLA-Cw6 allele carriers and response to ustekinumab has the potential to impact treatment decisions. Patients and methods: Differences in Psoriasis Activity and Severity Index 50, 75, and 90; Nail Psoriasis Severity Index; and Dermatology Life Quality Index at 16 weeks were evaluated between HLA-Cw6 allele carriers vs. non-carriers. Thirty patients with moderate-to-severe psoriasis under treatment with ustekinumab were included in our study. Results: There was no difference between the two groups with respect to Psoriasis Activity and Severity Index 50, 75, and 90 or in terms of change in Nail Psoriasis Severity Index or Dermatology Life Quality Index. Conclusion: In our retrospectively analyzed cohort, we could not detect the previously reported better response in HLA-Cw6+ vs. HLA-Cw6− patients. Keywords: human leukocyte antigen, Cw6, genetic variations, HLA-Cw6, ustekinumab
format	article
author	Anzengruber F Ghosh A Maul JT Drach M Navarini AA
author_facet	Anzengruber F Ghosh A Maul JT Drach M Navarini AA
author_sort	Anzengruber F
title	Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis
title_short	Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis
title_full	Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis
title_fullStr	Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis
title_full_unstemmed	Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis
title_sort	limited clinical utility of hla-cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/b23c615b37b24ed0ba058906bc897a55
work_keys_str_mv	AT anzengruberf limitedclinicalutilityofhlacw6genotypingforoutcomepredictioninpsoriasispatientsunderustekinumabtherapyamonocentricretrospectiveanalysis AT ghosha limitedclinicalutilityofhlacw6genotypingforoutcomepredictioninpsoriasispatientsunderustekinumabtherapyamonocentricretrospectiveanalysis AT mauljt limitedclinicalutilityofhlacw6genotypingforoutcomepredictioninpsoriasispatientsunderustekinumabtherapyamonocentricretrospectiveanalysis AT drachm limitedclinicalutilityofhlacw6genotypingforoutcomepredictioninpsoriasispatientsunderustekinumabtherapyamonocentricretrospectiveanalysis AT navariniaa limitedclinicalutilityofhlacw6genotypingforoutcomepredictioninpsoriasispatientsunderustekinumabtherapyamonocentricretrospectiveanalysis
_version_	1718402918260932608

Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis

Ejemplares similares